ATOSSA THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

19 Mar 2024 10:49:14 By NetDania Notify

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

19 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

18 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

12 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

22 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

07 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Issues Letter to Shareholders

09 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

04 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

20 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

13 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

09 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

18 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

14 Aug 2023 08:30:03 By Nasdaq GlobeNewswire

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

08 Aug 2023 09:00:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

20 Jul 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

13 Jul 2023 16:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

10 Jul 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

06 Jul 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

28 Jun 2023 09:15:00 By Nasdaq GlobeNewswire